These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 11032540)
41. Platelet glycoprotein IIb/IIIa inhibitors: overview and implications for the anesthesiologist. Chun R; Orser BA; Madan M Anesth Analg; 2002 Oct; 95(4):879-88. PubMed ID: 12351262 [No Abstract] [Full Text] [Related]
42. Guidelines for acute coronary syndrome without ST elevation. Ward DJ; Taylor R Lancet; 2002 Apr; 359(9314):1349; author reply 1350. PubMed ID: 11965312 [No Abstract] [Full Text] [Related]
43. Early clinical results with the new oral glycoprotein IIb/IIIa agents. Teirstein PS Am J Cardiol; 1999 May; 83(9A):12E-15E. PubMed ID: 10357576 [No Abstract] [Full Text] [Related]
44. Early invasive therapy of non ST-elevation acute coronary syndromes--combined with upstream antiplatelet therapy: yes--but how early? Niemelä K; Vikman S Eur Heart J; 2003 Aug; 24(15):1383-4. PubMed ID: 12909065 [No Abstract] [Full Text] [Related]
45. Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative. Fesmire FM; Peterson ED; Roe MT; Wojcik JF Am J Emerg Med; 2003 Jul; 21(4):302-8. PubMed ID: 12898487 [TBL] [Abstract][Full Text] [Related]
46. Management of acute coronary syndromes clinical guideline. Schamroth C S Afr Med J; 2002 Oct; 92(10):746-7; author reply 747-8. PubMed ID: 12432790 [No Abstract] [Full Text] [Related]
47. Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. Roe MT; Moliterno DJ J Emerg Med; 1999; 17(3):581-8. PubMed ID: 10338260 [No Abstract] [Full Text] [Related]
48. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. Gurbel PA; Serebruany VL J Thromb Thrombolysis; 2000 Dec; 10(3):217-20. PubMed ID: 11122540 [No Abstract] [Full Text] [Related]
49. [Eptifibatide in acute coronary syndromes. Comments on the practice guidelines in antithrombotic treatment]. Díaz de Rojas F; Ponte A; Cuenllas E Rev Esp Cardiol; 2000 Feb; 53(2):302-3. PubMed ID: 10734766 [No Abstract] [Full Text] [Related]
50. National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors? Knight CJ Heart; 2001 May; 85(5):481-3. PubMed ID: 11302983 [No Abstract] [Full Text] [Related]
51. Into the future with glycoprotein IIb/IIIa receptor antagonists. White N Drugs R D; 1999 May; 1(5):393-5. PubMed ID: 10566074 [No Abstract] [Full Text] [Related]
52. NICE appraisals and cardiology: glycoprotein IIb/IIIa inhibitors and acute coronary syndromes. Hyde T; Knight C Hosp Med; 2003 Nov; 64(11):638-9. PubMed ID: 14671871 [No Abstract] [Full Text] [Related]
58. Value of community-derived risk models for stratifying patients with non-ST elevation acute coronary syndromes. Wong CK; White HD Eur Heart J; 2005 May; 26(9):851-2. PubMed ID: 15781432 [No Abstract] [Full Text] [Related]
59. [New antiplatelet agents in the acute stage of coronary artery disease]. Chatot M; Schiele F Rev Prat; 2015 Mar; 65(3):339-40. PubMed ID: 26016191 [No Abstract] [Full Text] [Related]